AZ, Cellartis Extend Alliance Developing hESC-Derived Liver, Heart Cells | GenomeWeb

AstraZeneca and Cellartis this week announced that they have extended an existing collaboration to develop toxicology screening assays based on human embryonic stem cell-derived hepatocytes and cardiomyocytes.

The alliance, originally begun in 2006 and extended by two years, calls for the companies to develop assays for target and lead validation, compound screening, drug metabolism studies, and safety assessment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.